Study of Lanreotide to Treat Polycystic Kidney Disease

Bio2RDF uri

Study of Lanreotide to Treat Polycystic Kidney Disease

http://bio2rdf.org/clinicaltrials:NCT01616927

Bio2RDF identifier

NCT01616927

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT01616927

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT01616927

acronym [clinicaltrials_vocabulary:acronym]

DIPAK1

http://www.w3.org/2001/XMLSchema#string

anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]

300

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT01616927 arm group 05feb48e6eb643d3fbbedf29fbc8a04e [clinicaltrials_resource:NCT01616927/arm-group/05feb48e6eb643d3fbbedf29fbc8a04e]

NCT01616927 arm group 34334e2e4743ebaefc660f50e478e58c [clinicaltrials_resource:NCT01616927/arm-group/34334e2e4743ebaefc660f50e478e58c]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:deafc54841822e091885764b1029027b

brief summary [clinicaltrials_vocabulary:brief-summary]

Autosomal dominant poly ...... received standard care.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Study of Lanreotide to Treat Polycystic Kidney Disease

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Change in renal function serial eGFR measurements from month 3 until end of treatment visit (month 30) [clinicaltrials_resource:c8384822b1a1121d008d0b472598ab2f]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Change in renal function serial eGFR measurements from month 3 until end of treatment visit (month 30) [clinicaltrials_resource:0195c68107b331e58197eadabd97c639]

Change in renal function serial eGFR measurements from month 3 until end of treatment visit (month 30) [clinicaltrials_resource:40e5864aee13a602583ddee519cb2eab]

Change in renal function serial eGFR measurements from month 3 until end of treatment visit (month 30) [clinicaltrials_resource:63c45264f9de1447ed4f46a3e4f54953]

Change in renal function serial eGFR measurements from month 3 until end of treatment visit (month 30) [clinicaltrials_resource:79b46e2360429e67c4fb29c97eacad07]

Change in renal function serial eGFR measurements from month 3 until end of treatment visit (month 30) [clinicaltrials_resource:8bc752ff7d127422d5e215c7b2cbb664]

Change in renal function serial eGFR measurements from month 3 until end of treatment visit (month 30) [clinicaltrials_resource:aca3720af5d6cf0166e48f4290d866ac]

collaborator [clinicaltrials_vocabulary:collaborator]

University Medical Centre Groningen [clinicaltrials_resource:ac928994a2de14c1f49f9e20298a8114]

completion date [clinicaltrials_vocabulary:completion-date]

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

detailed description [clinicaltrials_vocabulary:detailed-description]

Aims: First, to ...... Lanreotide is well tolerated

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT01616927 [clinicaltrials_resource:6c4120d490098f60a0aa20882d420980]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2012-06-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Lanreotide [clinicaltrials_resource:6fa19961c057a5100791474bbe8ed0d7]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Lanreotide [clinicaltrials_resource:05feb48e6eb643d3fbbedf29fbc8a04e]

Somatostatin [clinicaltrials_resource:90205c88a671a50621ed64e77c86b7fc]

Angiopeptin [clinicaltrials_resource:b5a22ed6a8d78563379b89fd804db18f]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

ADPKD

http://www.w3.org/2001/XMLSchema#string

lanreotide

http://www.w3.org/2001/XMLSchema#string

polycystic kidney

http://www.w3.org/2001/XMLSchema#string

polycystic liver

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

University Medical Centre Groningen [clinicaltrials_resource:ac928994a2de14c1f49f9e20298a8114]

link [clinicaltrials_vocabulary:link]

General description of the DIPAK consortium, including the DIPAK intervention study [clinicaltrials_resource:06b2ddc6864078b3a22f3d540a3c7925]

Link to the full protocol on The Lancet's web site [clinicaltrials_resource:c08630a3780c44d010c41e6bb7daf33c]

location [clinicaltrials_vocabulary:location]

University Medical Center Groningen [clinicaltrials_resource:c769e7a51dd54cb69c3e257867a033f4]

nct id [clinicaltrials_vocabulary:nct-id]

NCT01616927

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

The DIPAK 1 Study: A Randomise ...... t Disease Progression in ADPKD

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

DIPAK1

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Ron Gansevoort, MD, PhD [clinicaltrials_resource:4030ab112447b152a225563c51546ac8]

overall status [clinicaltrials_vocabulary:overall-status]

Active, not recruiting [clinicaltrials_resource:a6bc1606956390bcd6a391faced78809]

oversight [clinicaltrials_vocabulary:oversight]

Netherlands: Medical Ethics Review Committee (METC) [clinicaltrials_resource:aeb2dc7fe4546b20e213a47d343d8593]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2017-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

reference [clinicaltrials_vocabulary:reference]

24342522 [pubmed:24342522]

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:16050e587f1cd36f035dca3245184d4f]

secondary id [clinicaltrials_vocabulary:secondary-id]

2011-005017-37

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

University Medical Centre Groningen [clinicaltrials_resource:ac928994a2de14c1f49f9e20298a8114]

start date [clinicaltrials_vocabulary:start-date]

2012-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT01616927 study design [clinicaltrials_resource:cdc60929db28cf77ad6755105c04b9b6]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT01616927

verification date [clinicaltrials_vocabulary:verification-date]

2015-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT01616927

http://www.w3.org/2001/XMLSchema#string